REG - Aptamer Group PLC - Contract extension with global pharma partner

AptamerAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250818:nRSR6181Va&default-theme=true

RNS Number : 6181V  Aptamer Group PLC  18 August 2025

 

18 August 2025

 

Aptamer Group plc

 

("Aptamer", the "Company" or the "Group")

 

Contract extension and new work order with top 5 global pharma partner
Follow-on agreement advances Optimer® binders into a fully functional ELISA
assay, retaining IP for future licensing opportunities

 

Aptamer Group plc (AIM: APTA), the leading developer of next-generation
synthetic binders delivering innovation to the life science industry, is
pleased to announce a contract extension, entailing a new work order, with a
top 5 global pharmaceutical company.

 

As previously announced in the Company's commercial trading update on 6
November 2024, following the successful completion of a project for the
development of Optimer® binders to support an ELISA assay, Aptamer has now
secured an extension to this project.

 

This paid-for extension involves the conversion of these binders into a fully
functional ELISA assay. This progression demonstrates the efficacy of
Aptamer's Optimer® technology in meeting the partner's requirements and
advances the project into assay development.

 

Aptamer retains ownership of the intellectual property associated with these
binders, positioning the Company to potentially establish commercialisation
licenses in the future. This extension underscores the Group's ability to
deliver high-quality results that foster ongoing partnerships with leading
pharmaceutical companies.

 

Dr Arron Tolley, Chief Executive Officer of Aptamer Group said: "We are
delighted to have successfully completed the initial binder development phase
for this top 5 pharma partner and to now extend our collaboration into assay
conversion.

 

This milestone not only validates the performance of our Optimer® platform
but also highlights its potential for broader applications in diagnostics and
therapeutics. Retaining IP ownership provides us with opportunities for future
licensing revenues, aligning with our strategy to build long-term value
through repeat business and commercialisation pathways.

 

We look forward to providing further updates as this and other projects
progress."

 

- Ends -

 

For further information, please contact:

 

 Aptamer Group plc                                               +44 (0) 1904 217 404 

 Dr Arron Tolley, Chief Executive Officer
 SPARK Advisory Partners Limited - Nominated Adviser             +44 (0) 20 3368 3550 

 Andrew Emmott / Jade Bayat 
 Turner Pope Investments (TPI) Limited - Broker                  +44 (0) 20 3657 0050 

 James Pope / Andrew Thacker 
 Northstar Communications Limited - Investor Relations           +44 (0) 113 730 3896

 Sarah Hollins

 

About Aptamer Group

 

Aptamer Group is a leading developer of next-generation synthetic binders
delivering innovation to the life sciences industry. The Group develops
Optimer® binders, advanced molecules that work like antibodies by attaching
to specific targets in the body. These binders are used in medicine,
diagnostic tests, and research tools, offering benefits like high stability,
reliable performance, and lower costs compared to traditional antibodies.

 

Aptamer operates a fee-for-service business in the US$210 billion market for
antibody alternatives, working with all top 10 global pharmaceutical
companies. It is also building valuable Optimer® assets with partners, aiming
for future licensing revenue.

 

Founded in 2008, the Group listed on the London Stock Exchange AIM market in
December 2021 and is headquartered in York, UK.

 

To register for news alerts by email go
to https://aptamergroup.com/investors/investor-news-email-alerts/
(https://aptamergroup.com/investors/investor-news-email-alerts/)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTPKABQQBKDNFD